X

Drug Profile

Research programme: thyroid hormone receptor agonists - Karo Pharma

Alternative Names: Research programme: glaucoma therapeutics - Karo Pharma

Latest Information Update: 21 Dec 2016

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Karo Bio
Class
Mechanism of Action Thyroid hormone receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Discontinued Glaucoma

Most Recent Events

12 Sep 2006 Discontinued - Preclinical for Glaucoma in Sweden (Ophthalmic)
31 Dec 2001 SIFI have signed a one-year agreement with Karo Bio
07 May 2001 Karo Bio's thyroid hormone receptor agonist eye drops are available for licensing

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com